GBP5 and cancer: In conclusion, the high expression levels of GBP5 are associated with poor prognosis in OSCC patients and caner malignancy including cell growth, invasion/migration, and cancer stemness of OSCC, indicating that GBP5 may be a potential diagnostic biomarker and therapeutic target for OSCC patients in the future.